MX2014005433A - Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. - Google Patents

Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.

Info

Publication number
MX2014005433A
MX2014005433A MX2014005433A MX2014005433A MX2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A
Authority
MX
Mexico
Prior art keywords
proportion
compositions
composition
methods
disease
Prior art date
Application number
MX2014005433A
Other languages
English (en)
Spanish (es)
Inventor
Thomas W Boileau
Jennifer Brulc
Ravindranath Sreedhar Menon
Original Assignee
Gen Mills Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Mills Inc filed Critical Gen Mills Inc
Publication of MX2014005433A publication Critical patent/MX2014005433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2014005433A 2011-11-04 2012-11-01 Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. MX2014005433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555800P 2011-11-04 2011-11-04
PCT/US2012/063008 WO2013067146A1 (en) 2011-11-04 2012-11-01 Methods and compositions for modulating gastrointestinal bacteria to promote health

Publications (1)

Publication Number Publication Date
MX2014005433A true MX2014005433A (es) 2014-08-22

Family

ID=48192757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005433A MX2014005433A (es) 2011-11-04 2012-11-01 Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.

Country Status (11)

Country Link
US (1) US20150209383A1 (enExample)
EP (1) EP2773357A4 (enExample)
JP (1) JP2014532710A (enExample)
KR (1) KR20140093252A (enExample)
CN (1) CN104159588A (enExample)
AU (1) AU2012332491A1 (enExample)
BR (1) BR112014010660A2 (enExample)
CA (1) CA2854398A1 (enExample)
IN (1) IN2014CN04055A (enExample)
MX (1) MX2014005433A (enExample)
WO (1) WO2013067146A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
US10398745B2 (en) 2016-01-26 2019-09-03 Fujifilm Corporation Agent for reducing the number of intestinal bacteria, food, and pharmaceutical product
US20190070204A1 (en) * 2016-03-14 2019-03-07 B Food Science Co., Ltd. Proliferative agent for faecalibacterium
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND APPLICATION THEREOF
WO2018220237A1 (en) 2017-06-02 2018-12-06 Goodgut Sl Grape skin for use in the treatment of dysbiosis
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3466417A1 (en) * 2017-10-04 2019-04-10 Sorbonne Université Compounds for the prevention and treatment of glucose intolerance related conditions and obesity
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CN109998112B (zh) * 2017-12-22 2024-05-14 奥地利商艾尔柏有限公司 红蝽杆菌纲促进肠道健康的用途
US20210100831A1 (en) * 2018-02-14 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Polydextrose for the treatment of inflammatory diseases
WO2019216815A1 (en) * 2018-05-09 2019-11-14 Carbiotix Ab Method for measuring and improving gut health
CN112218646B (zh) * 2018-05-31 2024-06-11 深圳华大生命科学研究院 一种组合物及其应用
JP7811843B2 (ja) 2018-07-19 2026-02-06 ペンデュラム セラピューティクス， インコーポレイテッド 微生物生着のための方法および組成物
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
EP4041264A1 (en) * 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
KR102174095B1 (ko) * 2019-12-11 2020-11-05 주식회사 에이치이엠 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
WO2021184008A1 (en) * 2020-03-13 2021-09-16 Fitbiomics Inc. Probiotic compositions for improving human health and athletic performance
JP7824034B2 (ja) * 2020-04-16 2026-03-04 サンスター株式会社 フィーカリバクテリウム属細菌増殖用組成物、酪酸産生増加用組成物、及び腸内環境改善用組成物
JP2024518270A (ja) * 2021-05-06 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法
EP4436407A1 (en) 2021-11-22 2024-10-02 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0394655A (ja) * 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
JP4328473B2 (ja) * 2001-04-09 2009-09-09 雪印乳業株式会社 肥満予防改善飲食品
FI20020078A7 (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
JP2003334025A (ja) * 2002-05-15 2003-11-25 Toyo Shinyaku:Kk 健康食品
NZ537499A (en) * 2002-08-06 2007-01-26 Danisco Use of lactobacillus to produce exopolysaccharides in food and pharmaceutical compositions
GB0302872D0 (en) * 2003-02-10 2003-03-12 Univ Liverpool Treatment of inflammatory bowel disease
AU2008256938B2 (en) * 2007-05-23 2013-02-28 Tate & Lyle Ingredients Americas Llc Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition
GB0903016D0 (en) * 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
MX2011011659A (es) * 2009-05-07 2012-02-28 Tate & Lyle Ingredients France SAS Composiciones y metodos para elaborar alfa-(1,6) oligodextranos ramificados en alfa-(1,2).

Also Published As

Publication number Publication date
CN104159588A (zh) 2014-11-19
EP2773357A1 (en) 2014-09-10
KR20140093252A (ko) 2014-07-25
BR112014010660A2 (pt) 2017-05-09
JP2014532710A (ja) 2014-12-08
WO2013067146A1 (en) 2013-05-10
AU2012332491A1 (en) 2014-05-29
IN2014CN04055A (enExample) 2015-10-23
CA2854398A1 (en) 2013-05-10
EP2773357A4 (en) 2015-08-26
US20150209383A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IN2014CN04055A (enExample)
Liu et al. Gut microbiota: A new target for T2DM prevention and treatment
Fan et al. Research progress of gut microbiota and obesity caused by high-fat diet
Li et al. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice
Xu et al. Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems
Song et al. Dietary anthocyanin-rich extract of açai protects from diet-induced obesity, liver steatosis, and insulin resistance with modulation of gut microbiota in mice
Quezada et al. Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics
Yuan et al. Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice
Zhang et al. Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha
Flaig et al. Treatment of dyslipidemia through targeted therapy of gut microbiota
Shang et al. Characterization of fecal fat composition and gut derived fecal microbiota in high-fat diet fed rats following intervention with chito-oligosaccharide and resistant starch complexes
Kootte et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus
Zhou et al. Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring
Panpetch et al. Candida administration worsens cecal ligation and puncture-induced sepsis in obese mice through gut dysbiosis enhanced systemic inflammation, impact of pathogen-associated molecules from gut translocation and saturated fatty acid
JP2015523362A5 (enExample)
Kobyliak et al. Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention
BR112012002639A2 (pt) métodos e composições para melhorar a saude gastrintestinal
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
WO2010081079A3 (en) Composition and method for treatment of diabetes
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
MX2012003459A (es) Composicion y metodo para el tratamiento de la diabetes.
Yang et al. Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora
Liu et al. Salidroside protects mice from high-fat diet-induced obesity by modulating the gut microbiota
Aldamarany et al. Perilla, sunflower, and tea seed oils as potential dietary supplements with anti-obesity effects by modulating the gut microbiota composition in mice fed a high-fat diet
Zheng et al. The role of bound polyphenols in the anti-obesity effects of defatted rice bran insoluble dietary fiber: An insight from multi-omics

Legal Events

Date Code Title Description
FA Abandonment or withdrawal